BioAge Labs Inc. announced additional positive interim data from its ongoing Phase 1 clinical trial of BGE-102, a novel, orally available, brain-penetrant NLRP3 inhibitor developed for patients with cardiovascular risk factors. In the multiple ascending dose cohort, obese participants with elevated hsCRP receiving 120 mg once daily showed an 86% reduction in hsCRP at Day 14, with 93% of participants reaching normalized levels. The study also reported significant reductions in IL-6 and fibrinogen. BGE-102 was well tolerated, with adverse events described as infrequent, mild to moderate, and self-limited, and no dose-limiting toxicities observed. Full Phase 1 data, including results from additional cohorts, are anticipated in the first half of 2026, and a Phase 2a study is planned to initiate in the same timeframe. Additional figures and data are available in the company's corporate presentation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bioage Labs Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9623622) on January 12, 2026, and is solely responsible for the information contained therein.